semaglutide weight loss deer valley GLP-1 Clinic Tampa, FL Semaglutide Injections for Weight Loss

Semaglutide belongs to the drug class called glucagon-like peptide-1 (GLP-1) agonists

This Phase 3b trial evaluated a higher investigational dose of semaglutide (7.2 mg, compared to the currently approved 2.4 mg dose) in 1,407 adults with obesity without diabetes over 72 weeks: The 7.2 mg dose achieved an average weight loss of approximately 1921% of total body weight approaching results previously seen only with tirzepatide (Zepbound) Nearly half of participants on the 7.2 mg dose achieved 20% weight loss a threshold previously associated only with bariatric surgery or the most potent dual-agonist medications The currently approved 2.4 mg dose achieved approximately 16% average weight loss in the same trial, consistent with earlier STEP data While the 7.2 mg dose is not yet FDA-approved, the STEP UP data represent an exciting frontier in semaglutide therapy and underscore the continued evolution of this class of medications

Tools to stay on track , including meal logging, progress tracking, and practical resources

Belmar Pharma Solutions has been specifically identified as one of their pharmacy partners